Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Hematologic and biochemical reference intervals depend on many factors, including age. A review of the literature highlights the lack of reference intervals for 6-wk-old specific pathogen free (SPF) Hampshire-Yorkshire crossbred pigs. For translational research, 6-wk-old pigs represent an important animal model for both human juvenile colitis and diabetes mellitus type 2 given the similarities between the porcine and human gastrointestinal maturation process. The aim of this study was to determine reference intervals for hematological and biochemical parameters in healthy 6-wk-old crossbred pigs. Blood samples were collected from 66 clinically healthy Hampshire-Yorkshire pigs. The pigs were 6 wks old, represented both sexes, and were housed in a SPF facility. Automated hematological and biochemical analysis were performed using an ADVIA 120 Hematology System and a Cobas 6000 C501 Clinical Chemistry Analyzer.
Results: Reference intervals were calculated using both parametric and nonparametric methods. The mean, median, minimum, and maximum values were calculated.
Conclusion: As pigs are used more frequently as medical models of human disease, having reference intervals for commonly measured hematological and biochemical parameters in 6-wk-old pigs will be useful. The reference intervals calculated in this study will aid in the diagnosis and monitoring of both naturally occurring and experimentally induced disease. In comparison to published reference intervals for older non SPF pigs, notable differences in leukocyte populations, and in levels of sodium, potassium, glucose, protein, and alkaline phosphatase were observed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898366 | PMC |
| http://dx.doi.org/10.1186/2049-1891-5-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics.
Eur J Nucl Med Mol Imaging
September 2025
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Purpose: Cardiac noradrenergic denervation visualized by meta-[I]iodobenzylguanidine ([I]MIBG) imaging supports the diagnosis of Parkinson's disease (PD). Recently, meta-[F] fluorobenzylguanidine ([F]MFBG) PET demonstrated favorable imaging characteristics compared with [I]MIBG scintigraphy for neuroendocrine tumors. We assessed [F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients.
View Article and Find Full Text PDFPharmacokinetic Study and Bioequivalence Evaluation of Two Sustained-Release Tablets of Tamsulosin in Healthy Chinese Subjects Under Fasting and Postprandial Conditions.
Clin Pharmacol Drug Dev
September 2025
Phase I Clinical Research Centre, Wuhan Pulmonary Hospital, Wuhan, China.
Tamsulosin is a highly selective α1A adrenergic receptor antagonist that can relax smooth muscles in the urethra, bladder neck, and prostate and improve urinary disorders. It is therefore widely used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. The aim of this study is to evaluate the pharmacokinetic (PK) characteristics and bioequivalence of 2 different formulations (tamsulosin sustained-release tablets and tamsulosin sustained-release capsules) in healthy Chinese subjects.
View Article and Find Full Text PDFBackground: Based on the widespread use of the systemic immune-inflammation index (SII), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio (LMR), markers, we aimed to calculate and compare the reference intervals (RIs) of these indices in adults, using both nonparametric method according to the Clinical and Laboratory Standards Institute's (CLSI) EP28-A3C:2010 guideline and refineR algorithm using a large dataset.
Methods: We analyzed data from 293,585 adults (18 - 65 years) retrospectively obtained from complete blood count results (using laboratory information system). The study involved a two-stage outlier exclusion process.
Applying expertise: Extrapleural pneumonectomy and extended pleurectomy decortication in the management of Masaoka-Koga stage IV thymoma.
JTCVS Open
August 2025
Department of Thoracic Surgery, Glenfield Hospital, University Hospitals of Leicester Trust, Leicester, United Kingdom.
Objectives: The European Society of Medical Oncology supports the use of surgery with adjuvant radiotherapy in resectable Masaoka-Koga Stage IV thymomas. We explore the role of extended pleurectomy decortication (EPD) and extrapleural pneumonectomy (EPP) in the management of patients with Masaoka-Koga stage IV thymic tumors with pleural involvement from our single-center experience.
Methods: We conducted a retrospective analysis of patients who had undergone extended resections over a 10-year period for Masaoka-Koga stage IV thymomas at our thoracic unit in the United Kingdom.
Is segmentectomy actually superior to lobectomy for early-stage lung cancer? A discrepancy between the JCOG0802 trial and real-world practice.
JTCVS Open
August 2025
Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Objective: To evaluate whether results of the JCOG0802/WJOG4607L trial, which demonstrated the superiority of segmentectomy over lobectomy in terms of overall survival for patients with peripheral small-sized lung cancer, are applicable to clinical practice.
Methods: In this single-center retrospective analysis, we categorized patients who underwent lobectomy or segmentectomy during the enrollment period of the JCOG0802/WJOG4607L trial into 3 groups: patients enrolled in the trial (Cohort A), patients who were eligible but not enrolled (Cohort B), and ineligible patients (Cohort C). We assessed whether trial participants reflected typical patients seen in clinical practice (representativeness) and whether trial results could be applied in routine practice (generalizability) by comparing patient characteristics and survival between cohorts, using Cohort A as the reference.